What is Evaxion Biotech A/S (EVAX)?

Evaxion Biotech A/S (EVAX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of EVAX?

The current price of EVAX is $3.11. Prices are updated in real time on Stocks360.

What is EVAX's price-to-earnings (PE) ratio?

EVAX's trailing twelve-month PE ratio is -0.51, based on current price and earnings per share data available on Stocks360.

What is EVAX's market capitalization?

EVAX's market capitalization is $19,644,539.00, placing it in the small-cap tier.

Evaxion Biotech A/S (EVAX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$3.11

Market Cap

$19.64M

PE (TTM)

-0.51

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.27

Day Range

$3.04 – $3.19

52-wk Range

$2.72 – $6.92

Avg Volume

N/A

Volume

51.04K

Evaxion Biotech A/S (EVAX) is a publicly traded company in the Healthcare sector. Latest price: $3.11. Market cap $19.64M. Trailing PE -0.51. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 5 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-29 · $5.75 2026-10-28 · $3.11 (-45.91%)

Earnings

Most Recent

Aug 13, 2026

EPS $-0.01 vs est. $-0.01

Beat by $0.00

Next Earnings

Nov 19, 2026

EPS estimate $-0.01

Proprietary Signals

Signal snapshot temporarily unavailable.

About Evaxion Biotech A/S

Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.51×
P/S (TTM)	2.62×
P/B	0.14×
PEG	0.00×
P/FCF (TTM)	0.00×
EV / EBITDA	-1.28×
EV / Sales	1.70×
Earnings Yield	-667.18%
Free Cash Flow Yield	0.00%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$12.75M
Revenue (TTM)	$7.49M
Net Income (TTM)	-$131.06M
Free Cash Flow (TTM)	$659.11K
Net Debt	-$6.89M
Working Capital	$12.72M
Gross Margin	100.00%
Operating Margin	-115.98%
Net Margin	-115.49%
Return on Equity	-61.39%
Return on Invested Capital	-46.68%